Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. CEO JD Finley presented the company's top five investment highlights for 2025. The presentation is now available for viewing on the company's website and through the conference platform.
Palisade Bio (Nasdaq: PALI), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per malattie autoimmuni, infiammatorie e fibrotiche, ha partecipato alla Conferenza Virtuale per Investitori 'Top 5 per il '25' On-Demand. Il CEO JD Finley ha presentato i cinque principali punti di investimento dell'azienda per il 2025. La presentazione è ora disponibile per la visione sul sito web dell'azienda e attraverso la piattaforma della conferenza.
Palisade Bio (Nasdaq: PALI), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias para enfermedades autoinmunes, inflamatorias y fibróticas, ha participado en la Conferencia Virtual para Inversores 'Top 5 para el '25' On-Demand. El CEO JD Finley presentó los cinco principales aspectos de inversión de la empresa para 2025. La presentación ya está disponible para su visualización en el sitio web de la empresa y a través de la plataforma de la conferencia.
Palisade Bio (Nasdaq: PALI)은 자가면역, 염증 및 섬유화 질환에 대한 치료제를 개발하는 데 주력하는 임상 단계의 생명공학 회사로, '25년을 위한 상위 5개' 가상 투자자 회의에 참여했습니다. CEO JD Finley는 2025년을 위한 회사의 주요 투자 하이라이트 5가지를 발표했습니다. 발표 내용은 이제 회사 웹사이트와 회의 플랫폼을 통해 시청할 수 있습니다.
Palisade Bio (Nasdaq: PALI), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour les maladies auto-immunes, inflammatoires et fibrosantes, a participé à la conférence virtuelle pour investisseurs 'Top 5 pour '25' On-Demand. Le PDG JD Finley a présenté les cinq principaux points d'investissement de l'entreprise pour 2025. La présentation est désormais disponible en visionnage sur le site web de l'entreprise et via la plateforme de la conférence.
Palisade Bio (Nasdaq: PALI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapeutika für Autoimmun-, entzündliche und fibrotische Erkrankungen konzentriert, hat an der virtuellen Investorenkonferenz 'Top 5 für '25' On-Demand teilgenommen. CEO JD Finley präsentierte die fünf wichtigsten Investitionshighlights des Unternehmens für 2025. Die Präsentation ist jetzt auf der Unternehmenswebsite und über die Konferenzplattform verfügbar.
- None.
- None.
On-demand video webcast now available here
Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference.
As part of the event, JD Finley, Chief Executive Officer of Palisade Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors and News section of the Company’s website (palisadebio.com).
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the SAD portion of the Company’s Phase 1b/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b/2a clinical study. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company is heavily dependent on the success of PALI-2108, which is in the early stages of clinical development and may not successfully progress through clinical development or receive regulatory approval; preliminary clinical study results or the results from earlier preclinical studies may not be predictive of final or future results and unexpected adverse side effects or inadequate efficacy of PALI-2108 may limit its development, regulatory approval and/or commercialization; the Company needs to raise significant additional funds to support its operations and the continued development of PALI-2108; the timing and outcome of the Company’s current and anticipated clinical studies related to its product candidates; indications of use and estimates about the size and growth potential of the markets for the Company’s product candidates, and its ability to serve those markets, including any potential revenue generated; the Company’s ability to maintain the Nasdaq listing of its securities; the Company’s ability to compete effectively in a competitive industry; the Company’s ability to identify and qualify manufacturers to provide API and manufacture drug product; the Company’s ability to enter into commercial supply agreements; the Company’s ability to attract and retain key scientific or management personnel; the accuracy of the Company’s estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and the impact of any global event on the Company’s business, and operations, and supply. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What did Palisade Bio (PALI) present at the Virtual Investor Top 5 for '25 Conference?
Where can investors watch Palisade Bio's (PALI) Top 5 for '25 presentation?
What therapeutic areas does Palisade Bio (PALI) focus on?
When did Palisade Bio (PALI) participate in the Virtual Investor Conference?
